NASDAQ:IDYA
IDEAYA Biosciences Inc. Stock News
$40.50
-1.03 (-2.48%)
At Close: May 17, 2024
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
12:00am, Tuesday, 04'th Aug 2020
QIAGEN reports full results for second quarter and first half of 2020
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
$100.00 Million in Sales Expected for IDEAYA Biosciences (NASDAQ:IDYA) This Quarter
01:38am, Sunday, 19'th Jul 2020
Equities research analysts expect IDEAYA Biosciences (NASDAQ:IDYA) to post $100.00 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for IDEAYA Biosciences’
IDEAYA Biosciences (IDYA) Gets a Buy Rating from Oppenheimer - Markets
09:47am, Friday, 17'th Jul 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a price
IDEAYA Biosciences (IDYA) Receives a Buy from H.C. Wainwright - Markets
01:43pm, Thursday, 16'th Jul 2020
H.C. Wainwright analyst Edward White maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that it has met the clinical prot
IDEAYA Biosciences (NASDAQ:IDYA) Upgraded to Buy by Zacks Investment Research
06:30pm, Wednesday, 15'th Jul 2020
IDEAYA Biosciences (NASDAQ:IDYA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The br
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the Company will participate in t
Vaccine Makers BioNTech, Moderna, And Novavax Set To Run Higher
12:00am, Tuesday, 14'th Jul 2020
Stocks Analysis by Harry Boxer covering: KB Home, Vaxart Inc, Novavax Inc, Altimmune Inc. Read Harry Boxer's latest article on Investing.com
Osmotica's FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
11:57am, Monday, 13'th Jul 2020
Osmotica gets FDA approval for Droopy Eyelid Treatment. NextCure advances solid tumor trial of NC410.
IDEAYA Biosciences (NASDAQ:IDYA) Upgraded to Overweight by JPMorgan Chase & Co.
07:08am, Monday, 13'th Jul 2020
IDEAYA Biosciences (NASDAQ:IDYA) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, Briefing.com Automa
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor
10:00am, Thursday, 09'th Jul 2020
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phas
The
